Potential drug-drug interactions in post-CCU of a teaching hospital

Iranian Journal of Pharmaceutical Research

Volumn 12, Issue 1, 2013, Pages 243-248

  Aghajani, Mohammad Haji ^a   Sistanizad, Mohammad ^a   Abbasinazari, Mohammad ^a   Ghamsari, Mahdieh Abiar ^a   Ayazkhoo, Ladan ^a   Saf, Olia ^a   Kazemi, Katayoon ^a   Kouchek, Mehran ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adverse drug effect; Drug interaction; Patient safety; Post CCU

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CARVEDILOL; CLOPIDOGREL; GLYCERYL TRINITRATE; MAGNESIUM HYDROXIDE; METOPROLOL; OMEPRAZOLE; PANTOPRAZOLE; SALBUTAMOL; SPIRONOLACTONE; WARFARIN;

ADULT; AGED; ARTICLE; CORONARY CARE UNIT; CROSS-SECTIONAL STUDY; DRUG COMBINATION; DRUG POTENTIATION; DRUG USE; FEMALE; HUMAN; INFORMATION PROCESSING; IRAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ETHICS; PATIENT MONITORING; PATIENT SAFETY; PHARMACIST; PHYSICIAN; PROSPECTIVE STUDY; RISK ASSESSMENT; TEACHING HOSPITAL; TOXICITY;

EID: 84874679768     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. th ed. Pharmaceutical Press: London (2008) 12-64.
2. Sandson N, Drug-drug interactions: the silent epidemic. Psychiatr. Serv. (2005) 56: 22-24.
3. Chris Raich MA, Teri Dunsworth. Drug Interactions. West Virginia University School of Pharmacy, Drug Information Center (1997).
4. DiPiro JT, Hooker KD, Sherman JC, Gaines MG and Wynn JJ. Effect of experimental hemorrhagic shock on hepatic drug elimination. Crit. Care. Med. (1992) 20: 810-815.
5. Kennedy JM and Riji AM. Effects of surgery on the pharmacokinetic parameters of drugs. Clin. Pharmacokinet (1998) 35: 293-312.
6. Tari L, Anwar S, Liang S, Cai J and Baral C. Discovering drug-drug interactions: a text-mining and reasoning approach based on properties of drug metabolism. Bioinformatics (2010) 26: 547-553.
7. Lima RE and De Bortoli Cassiani SH. Potential drug interactions in intensive care patients at a teaching hospital. Rev. Lat. Am. Enfermagem (2009) 17: 222-227.
8. Zhang L, Zhang YD, Zhao P and Huang SM. Predicting drug-drug interactions: an FDA perspective. AAPS J (2009) 11: 300-306.
9. Keiding S. Drug administration to liver patients: aspects of liver pathophysiology. Semin Liver Dis. (1995) 15: 268-282.
10. Nolan PE Jr and Marcus FI. Cardiovascular Drug Use in the Elderly.Am. J. Geriatr. Cardiol. (2000) 9: 127-129.
11. Lexi-Interact™ Online. 2011, UpToDate 19.1.
12. Moura C, Prado N and Acurcio F. Potential drug-drug interactions associated with prolonged stays in the intensive care unit: a retrospective cohort study. Clin. Drug. Investig. (2011) 31: 309-316.
13. Moura CS, Acurcio FA and Belo NO. Drug-drug interactions associated with length of stay and cost of hospitalization. J. Pharm. Pharm. Sci. (2009) 12: 266-272.
14. Takarabe M, Okuda S, Itoh M, Tokimatsu T, Goto S and Kanehisa M. Network analysis of adverse drug interactions. Genome. Inform. (2008). 20252-20259.
15. Stanton LA, Peterson GM, Rumble RH, Cooper GM and Polack AE. Drug-related admissions to an Australian hospital. J. Clin. Pharm. Ther. (1994) 19:341-347.
16. Roughead EE, Gilbert AL, Primrose JG and Sansom LN. Drug-related hospital admissions: a review of Australian studies published 1988-1996. Med. J. Aust. (1998) 168:405-408.
17. Goldberg RM, Mabee J, Chan L and Wong S. Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. Am. J. Emerg. Med. (1996) 14: 447-450.
18. Abbasi Nazari M and Khanzadeh-Moqhadam N. Evaluation of pharmacokinetic drug interactions in prescriptions of intensive care unit (ICU) in a teaching hospital. Iranian J. Pharm. Res. (2006) 5: 3215-3218.
19. Dallenbach MF, Bovier PA and Desmeules J. Detecting drug interactions using personal digital assistants in an out-patient clinic. QJM. (2007) 100:691-697.
20. Faulx MD and Francis GS, Adverse drug reactions in patients with cardiovascular disease. Curr. Probl. Cardiol. (2008) 33: 703-768.
21. Oertle M. Frequency and nature of drug-drug interactions in a Swiss primary and secondary acute care hospital. Swiss Medical Weekly (2012) 142.
22. Gagne JJ, Maio V and Rabinowitz C. Prevalence and predictors of potential drug-drug interactions in Regione Emilia-Romagna, Italy. J. Clin. Pharm. Ther. (2008) 33: 141-151.
23. Frelinger AL, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Brooks JK, Bhatt DL and Michelson AD. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J. Am. Coll. Cardiol. (2012) 59: 1304-1311.
24. Glassman PA, Simon B, Belperio P and Lanto A. Improving recognition of drug interactions: benefts and barriers to using automated drug alerts. Med. Care. (2002) 40: 1161-1171.
25. Chrischilles EA, Fulda TR, Byrns PJ, Winckler SC, Rupp MT and Chui MA. The role of pharmacy computer systems in preventing medication errors. J. Am. Pharm. Assoc. (Wash) (2002) 42: 439-448.
26. Roberts JS, Watrous ML, Schulz RM, Mauch RP and Nightengale BS. Quantifying the clinical signifcance of drug-drug interactions: scaling pharmacists' perceptions of a common interaction classifcation scheme. Ann. Pharmacother. (1996) 30: 926-934.
27. Weingart SN, Simchowitz B, Padolsky H, Isaac T, Seger AC, Massagli M, Davis RB and Weissman JS, An empirical model to estimate the potential impact of medication safety alerts on patient safety, health care utilization, and cost in ambulatory care. Arch Intern. Med. (2009)169: 1465-1473.
28. Ansari J, Drug interaction and pharmacist. J. Young. Pharm. (2010) 2: 326-331.